Company intelligence / Profile preview

ParlezChem

Ownership: Private
Development stage: Preclinical

Overview

ParlezChem is a company specializing in chemical literature informatics. It focuses on transforming scientific literature into accessible, structured data to support chemical and pharmaceutical research. There is no evidence that the company develops its own drug pipeline or clinical-stage products.[1]

Industry: Biomedical IT and Biomedical Data Platforms

Drug pipeline

2 assets

sulfameter

Pre-clinical

Indications: Sialidosis

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborates with academic researchers and government agencies such as the US EPA for computational toxicology and exposure studies[4]Works with professionals from universities like UNC Eshelman School of Pharmacy and organizations such as Leidos/EPA[3][4]

Beyond the preview

Go deeper on ParlezChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ParlezChem.

Explore the full profile